London South East | The UK's favourite investor portal.

Angle PLC Parsortix: Dynamic assessment of patient response

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

08 February 2021

For immediate release 8 February 2021

ANGLE plc ("the Company")

USE OF PARSORTIX SYSTEM ENABLES A DYNAMIC ASSESSMENT OF PATIENT RESPONSE TO TREATMENT IN NON-SMALL CELL LUNG CANCER

CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy

Findings support ANGLE's plan for the growth of a new "pharma services" business area using the Parsortix system as a biomarker for cancer drug trials allowing longitudinal monitoring of patients

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens (Athens) has published results of a new study undertaken in non-small cell lung cancer (NSCLC). This study demonstrates the utility of ANGLE's Parsortix(R) system for minimally invasive, longitudinal monitoring of changes in circulating tumour cell (CTC) gene expression in NSCLC patients with an EGFR mutation being treated with the tyrosine kinase inhibitor (TKI), Osimertinib (AstraZeneca's Tagrisso(R) ). Identifying these changes could help guide next-line therapy decisions and provide an important enhancement to monitoring patient response in cancer drug trials.

The Athens study used the Parsortix system to harvest CTCs in blood samples from 30 NSCLC patients on three occasions during the treatment cycle. The first sample was taken on enrolment in the study and before administration of the first treatment cycle of Osimertinib, the second following completion of the first cycle, and the third at progression of disease (PD). The harvested CTCs were analysed for gene expression of a broad range of biomarkers. These included epithelial, mesenchymal/epithelial to mesenchymal transition (EMT), stem cell markers and PD--L1. The authors note that they believe this is the first study on gene expression in CTCs at three different time points in patients being treated with Osimertinib.

The study showed that Parsortix, an epitope independent liquid biopsy system, was able to isolate CTCs from patients with a mesenchymal/EMT phenotype. This is of clinical significance given that mesenchymal/EMT biomarkers were present in CTCs in 60% of patients at baseline and 80% following one cycle of Osimertinib. EMT is implicated as a key mechanism in tumour cell survival, invasion, metastasis, and drug resistance in a range of cancers. It is also implicated in resistance to TKI treatment in NSCLC.

Furthermore, a statistically significant increase in PD-L1 positive CTCs was observed at disease progression (i.e. patients who did not respond to treatment with Osimertinib). This is in accordance with previous findings that attribute upregulation of PD-L1 with TKI resistance, and suggests that this cohort of patients, as identified by their CTC status, could bene

A non-binding MOU was signed with global aerospace and defence technology company, L3Harris Technologies which frames the intent to enter a global non-exclusive license agreement with Seeing Machines' Crew Training System, enhancing pilot training

Aftermarket Highlights:

-- Fleet revenue of A$15m for H1 2021 a significant contributor to the overall Company result, representing 16% growth on the previous period;

-- Guardian (Company Fleet solution) pipeline developed, alongside uninstalled hardware sales from H1 2021, and is expected to generate significantly increased revenue through to 30 June 2021, commensurate with previous periods;

-- Naturalistic driving data, a fundamental metric to Seeing Machines' ongoing technology roadmap, collected by Guardian has now reached over 5.8 billion kilometres;

-- Distribution partners around the world now totals fifteen across Asia Pacific, Europe, UK, Africa and The Americas.

Outlook:

Seeing Machines continues to trade in line with expectations for FY2021.

Paul McGlone, CEO of Seeing Machines commented: "The first half of FY2021 has been significant for the company and the results are pleasing. Despite the obvious ongoing challenges around the world, we are still seeing growth in our Aftermarket (Fleet) business and our engagement across the OEM business and associated industries (Automotive and Aviation), has never been stronger. We are encouraged by our continued engagement across a number of ongoing RFQs, which have increased significantly in both number and value, since 1 July 2020, to deliver Driver and Occupant monitoring system technology to carmarkers globally.

Our expanding ecosystem of partners across the Automotive sector, in particular, is extremely encouraging and we are very positive about the tie-ups with large, global semi-conductor companies that will enable Seeing Machines to provide options and cost-savings for OEMs, especially as regulation really starts to impact delivery schedules. And despite the obstacles we face with momentum in the Aviation industry due to Covid-19, I remain confident that our long-standing collaborations will bear fruit and that Seeing Machines will see growth across this business in the near-term."

The Company expects to publish its half year results in March 2021.

Seeing Machines Limited Half year trading update

Source: UK Regulatory (RNS & others)
TIDMSEE

RNS Number : 4289N

Seeing Machines Limited

01 February 2021

Seeing Machines Limited

1 February 2021

Half year trading update

Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, publishes a trading update for the six months to 31 December 2020 ("H1 2021").

The Company expects to report revenue for H1 2021 of A$18.1m (H1 2020: A$15.8m), a 14.6% increase. Total connected Guardian units at 31 December 2020 was 26,597, securing forward Annualised Recurring Revenues including royalties of A$15.5m (H1 2020: A$13.2m, +17.4%). This represents an increase of 3,182 Guardian units in H1 2021 with additional hardware sales of 3,371 units still to be connected. Cash position at 31 December 2020 of A$52.7m (H1 2020: A$38.1m).

Driver Monitoring System (DMS) technology continues to gain momentum as it becomes central to safety in all transport sectors. Regulatory and safety bodies in Europe have acknowledged its importance and this trend extends globally as the USA becomes focused on a road safety agenda to address risks posed by emerging semi- and fully-automated vehicle technologies.

Seeing Machines continues to grow despite the ongoing disruption caused to its key transport sectors by the global COVID-19 pandemic. FY2021 marks the start of production for two major Automotive OEM programs, one in Europe and one in North America, as well as one of many vehicles from an expanded program for an existing OEM customer, signalling the beginning of meaningful Automotive production royalty revenues.

OEM Highlights:

-- Three-pillar embedded product strategy launched, targeting the rapidly expanding camera-based interior monitoring market for automotive focused on its FOVIO Chip, the introduction of its Occula(TM) Neural Processing Unit and it's e-DME (embedded Driver Monitoring Engine);

-- Three-pillar strategy closely supports carmakers with a range of integration options for industry-leading DMS as they design cars to meet mounting safety standards and deliver more convenience features for their customers;

-- Over the next two years, Seeing Machines expects to be in full production with existing OEM customers on more than 30 distinct car models, ranging from world leading technology flagship brands to world sales volume leaders;

-- The Company is now formally working with additional global semi-conductor companies, Qualcomm Technologies and OmniVision Technologies, to extend the delivery of its DMS and partnerships within a growing ecosystem of Tier-1 customers;

-- Seeing Machines led the DMS industry with its formal launch of Occupant Monitoring System (OMS) technology to the Automotive market; and

-- A non-binding MOU was signed with global aerospace and defence technology

RNS Number : 2829N
Angle PLC
29 January 2021

For immediate release

29 January 2021

ANGLE plc ("the Company")

MAJOR EUROPEAN CONSORTIUM PUBLISHES RESULTS OF LARGE-SCALE INVESTIGATION DEMONSTRATING KEY ADVANTAGES OF parsoRtix system in lung cancer

Parsortix system demonstrates high capture rate of CTCs irrespective of biomarker status or phenotype

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the performance and technical capabilities of five circulating tumour cell (CTC) isolation platforms, in which key advantages of the Parsortix® system were identified. The CANCER-ID consortium is supported by Europe's Innovative Medicines Initiative (IMI) and is a Europe-wide Public-Private-Partnership aimed at the establishment of standard protocols for, and clinical validation of, blood-based biomarkers in order to drive wide adoption of liquid biopsy in clinical practice and pharma services.

CTCs are cancer cells present in the blood stream, which can be harvested from a simple blood test, providing minimally invasive access to solid tumours. In their latest research, the Consortium highlights that, when compared to other circulating biomarkers, the clear advantage of harvested CTCs is that they provide insight into RNA expression and proteins, which might provide additional detail to help inform more rational treatment decisions than ctDNA alone. As such, CTCs have the potential to develop superior assays for detection, analysis, and treatment of systemic cancer.

The group selected non-small cell lung cancer (NSCLC) cell lines for its initial focus because of the large number of available targeted therapies. This creates a need for predictive biomarkers to stratify patients and monitor treatment response. CTCs could be a valuable source of such relevant biomarkers. Two cell lines were used with a strong difference in both epithelial marker (EpCAM) expression (to test marker-dependent and marker independent platforms) and size (to test size-dependent isolation methods).

The research has shown that Parsortix performance was robust, with mean cell capture rates of 71% (EpCAM high cell line) and 67% (EpCAM low cell line). In comparison, the leading FDA approved antibody-based CTC system was unable to enrich EpCAM low cells. Parsortix was comparable to the leading antibody-based system with respect to time required for sample processing, staining and cell identification and was considerably faster than some other systems. The use of Transfix® blood collection tubes, utilised with Parsortix in this study, provided for 5 days' blood stability enhancing the practicability of sample management.

The research, which has been published in the peer-reviewed journal Clinical Chemistry, may be accessed via https://angleplc.com/library/publications/.

Latest Share Chat

Member Info for Morgank

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)